Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study

• Patrice Chevallier,
• Francoise Huguet,
• Emmanuel Raffoux,
• Anne Etienne,
• Thibaut Leguay,
• Francoise Isnard,
• Nelly Robillard,
• Thierry Guillaume,
• Jacques Delaunay,
• Aude Charbonnier,
• Arnaud Pigneux,
• Pierre Peterlin,
• Marie C. Bené,
• William A. Wegener,
• David M. Goldenberg,
• Hervé Dombret

Affiliations

Patrice Chevallier

Hematology Department, CHU Hotel-Dieu, Nantes

Francoise Huguet

Hematology Department, CHU, Toulouse

Emmanuel Raffoux

Hematology Department, Hôpital Saint-Louis, Paris

Anne Etienne

Hematology Department, Institut Paoli-Calmette, Marseille

Thibaut Leguay

Hematology Department, CHU, Bordeaux

Francoise Isnard

Hematology Department, Hopital Saint-Antoine, Paris

Nelly Robillard

Hematology/Biology Department, CHU Hotel-Dieu, Nantes, France

Thierry Guillaume

Hematology Department, CHU Hotel-Dieu, Nantes

Jacques Delaunay

Hematology Department, CHU Hotel-Dieu, Nantes

Aude Charbonnier

Hematology Department, Institut Paoli-Calmette, Marseille

Arnaud Pigneux

Hematology Department, CHU, Bordeaux

Pierre Peterlin

Hematology Department, CHU Hotel-Dieu, Nantes

Marie C. Bené

Hematology/Biology Department, CHU Hotel-Dieu, Nantes, France

William A. Wegener

Immunomedics, Inc., Morris Plains, NJ, USA

David M. Goldenberg

Immunomedics, Inc., Morris Plains, NJ, USA

Hervé Dombret

Hematology Department, Hôpital Saint-Louis, Paris